Wednesday, April 3, 2013. 1:00 - 5:00pm
San Diego Convention Center, Room 6E
San Diego, CA
Applying a Congruent Oncology Pharmacy Strategy - From Guidelines to Specialty Pharmacy:
Steps for Success with Multiple Myeloma
Hot Topics Include:
- Innovative oncology pharmacy benefit models and specialty pharmacy management services
- Decision-support tools, including comparative effectiveness research (CER), to improve therapeutic decision-making
- Response criteria to select and assess treatment success/outcomes
- Effective supportive care strategies in oncology
- Best practices in collaborating with the comprehensive care team to reduce treatment variability
|
Atheer Kaddis, PharmD
Senior Vice President, Sales and Business Development Diplomat Specialty Pharmacy Flint, MI |
|
Amrita Y. Krishnan, MD, FACP
Director, Multiple Myeloma Program Associate Director, Medical Education & Training Hematology & Hematopoietic Cell Transplantation Member, Hematologic Malignancies Program, Comprehensive Cancer Center Associate Professor of Hematology/HCT City of Hope Duarte, CA |
|
James Kenney, Jr., RPh, MBA, Activity Chairperson
Pharmacy Operations Manager Harvard Pilgrim Healthcare, Inc. Cambridge, MA |
|
Sandra Kurtin, RN, MS, AOCN, ANP
Hematology/Oncology Nurse Practitioner The University of Arizona Cancer Center Clinical Assistant Professor of Medicine Adjunct Clinical Assistant Professor of Nursing University of Arizona Tucson, AZ |
Who Should Attend?
This activity is designed to meet the educational needs of pharmacists, physicians and other healthcare professionals attending the AMCP 25th Annual Meeting & Expo.
Statement of Need/Program Overview
Oncology is often characterized by small trials, phase 2 data, surrogate efficacy endpoints (i.e., depth of response, time to progression), and relatively little data regarding "hard" endpoints, such as overall survival (OS). The nature of cancer also creates unique implications for how comparative effectiveness research (CER) should be applied. Enhanced competency is needed regarding the structure and delivery of oncology benefit designs, including supportive care. This symposium will illustrate a systematic approach to evaluate, select, and implement specialty pharmacy benefit design and management services to improve access and outcomes to appropriate therapies for patients with cancers such as multiple myeloma.
Educational Objectives
After completing this activity, the participant should be better able to:
- Review current and emerging clinical data to optimize therapeutic decision-making based on indicators of efficacy outcomes for MM treatments
- Demonstrate the use of CER as a decision-support tool to appropriately invest resources and reduce treatment variability with MM therapies
- Recommend methods to improve MM patient outcomes with supportive care within a health plan setting
- Evaluate innovative oncology pharmacy benefit models and specialty management services
- Provide accurate and appropriate counsel as part of the managed care treatment team
Agenda
Wednesday, April 3, 2013
San Diego Convention Center
Room 6E
| 1:00 pm | Registration and Lunch |
| 1:30 pm |
Opening Session
James Kenney, Jr., RPh, MBA, Activity Chairperson |
| 1:35 pm |
Optimizing Therapeutic Decision-Making for Multiple Myeloma: Classifying Indicators of Outcomes Amrita Y. Krishnan, MD, FACP |
| 2:20 pm |
Decision-Support Tools to Reduce Treatment Variability and Optimize Costs
James Kenney, Jr, RPh, MBA |
| 3:00 pm |
Collaborating to Improve Supportive Care Outcomes for Patients with Multiple Myeloma
Sandra Kurtin, RN, MS, AOCN, ANP |
3:40 pm |
Oncology Pharmacy Benefit Models and Specialty Management Services
Atheer Kaddis, PharmD |
4:25 pm | Audience Question and Answer Session | 4:55 pm |
Closing Remarks
Post-Activity Assessment and Evaluation |
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Postgraduate Institute for Medicine designates this live activity for a maximum of 3.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
|
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 3.5 contact hours (0.35 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0809-9999-13-260-L01-P)
Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.
Type of Activity: Application
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Impact Education, LLC, prior to the live event at (215) 619-8812.
Fee Information
No additional fee is required to attend this CPE/CME activity.
Pre-registration will close at 12:00 pm on April 1. Walk-in registration will be available at the time of the program.
If you have any questions, please call (215) 619-8812 or email info@impactedu.net.
Click here to register.